1. A106 SAFETY OF USTEKINUMAB WITH AND WITHOUT CONCOMITANT CORTICOSTEROIDS OR IMMUNOSUPPRESSANTS IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE CROHN'S DISEASE. (1st March 2018) Authors: Sands, B E; Gasink, C; Jacobstein, D; Ott, E; Lang, Y; Ramachandran, P; Ghosh, S Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 1(2018)Supplement 2 Page Start: 161 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A108 USTEKINUMAB IV INDUCTION RESULTS IN CROHN'S DISEASE SYMPTOM IMPROVEMENT WITHIN THE FIRST WEEK IN ANTI-TNF REFRACTORY PATIENTS. (1st March 2018) Authors: Sandborn, W; Yeager, B; Gasink, C; Hoops, T; Gao, L; Wang, Y; Jacobstein, D; Lee, S D; Hanauer, S Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 1(2018)Supplement 2 Page Start: 165 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A109 PREGNANCY OUTCOMES IN WOMEN EXPOSED TO USTEKINUMAB IN THE CROHN'S DISEASE CLINICAL DEVELOPMENT PROGRAM. (1st March 2018) Authors: Scherl, E; Jacobstein, D; Murphy, C; Ott, E; Gasink, C; Baumgart, D C; Abraham, B Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 1(2018)Supplement 2 Page Start: 166 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A141 DIFFERENT INDUCTION RESPONSE CRITERIA DO NOT INFLUENCE 1 YEAR RESPONSE AND REMISSION RATES OF USTEKINUMAB 90MG Q8W IN PHASE III PROGRAM. (1st March 2018) Authors: Naessens, D; Johanns, J; Gasink, C Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 1(2018)Supplement 1 Page Start: 242 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A147 RESPONSE AND REMISSION AFTER 16 WEEKS OF USTEKINUMAB– AN ALL PATIENTS ANALYSIS FROM THE UNITI CROHN'S STUDIES. (1st March 2018) Authors: Colombel, J F; Sloan, S; Gasink, C; Gao, L; Jacobstein, D; Lee, S D; Targan, S Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 1(2018)Supplement 2 Page Start: 219 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. A80 ENDOSCOPIC HEALING WITH USTEKINUMAB IN CROHN'S DISEASE: THE UNITI ENDOSCOPY SUB-STUDY. (1st March 2018) Authors: Feagan, B G; Sandborn, W; Gasink, C; Chan, D; Lang, Y; Pollack, P; Hanauer, S; Wolf, D; Jacobstein, D; Johanns, J; Szapary, P; Rutgeerts, P Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 1(2018)Supplement 1 Page Start: 137 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. A81 POOLED SAFETY ANALYSIS FROM THE USTEKINUMAB CROHN'S DISEASE AND PSORIATIC DISEASES PHASE 2 AND 3 TRIALS. (1st March 2018) Authors: Feagan, B G; Sands, B E; de Villiers, W; Ott, E; Gasink, C; Lang, Y; Szapary, P; Jacobstein, D; Ghosh, S Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 1(2018)Supplement 1 Page Start: 139 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. A85 EFFICACY AND SAFETY OF DOSE ADJUSTMENT AND DELAYED RESPONSE TO USTEKINUMAB IN MODERATE–SEVERE CROHN'S DISEASE: RESULTS FROM THE IM-UNITI MAINTENANCE STUDY. (1st March 2018) Authors: Sands, B E; Gasink, C; Jacobstein, D; Gao, L; Johanns, J; Szapary, P; Colombel, J F; Targan, S; Ghosh, S; Sandborn, W Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 1(2018)Supplement 1 Page Start: 147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. AODWE-006 Efficacy of ustekinumab for induction and maintenance of histological healing in patient's with crohn's disease. (17th June 2017) Authors: Li, K; Chan, D; Pollack, P; Jacobstein, D; Brodmerkel, C; Gasink, C; Feagan, B; Sandborn, W; Rutgeerts, P; Hertogh, G De Journal: Gut Issue: Volume 66(2017)Supplement 2 Page Start: A123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. OC-005 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A Human IL-12/23P40 MAB, in Moderate-Severe Crohn's Disease (CD) Refractory to anti-TNFΑ: UNITI-1. (17th August 2016) Authors: Rutgeerts, P; Gasink, C; Blank, M; Lang, Y; Johanns, J; Gao, L-L; Sands, B; Hanauer, S; Feagan, B; Targan, S; Ghosh, S; de Villiers, W; Colombel, J-F; Lee, SD; Desreumaux, P; Loftus, EV; Vermeire, S; Sandborn, WJ Journal: Gut Issue: Volume 65(2016)Supplement 1 Page Start: A3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗